FDA Approves Cytokinetics' Myqorzo Label Update With Phase 3 MAPLE-HCM Data
- Cytokinetics secured FDA clearance to add Phase 3 MAPLE-HCM results to the U.S. label for MYQORZO (aficamten).
- The previously reported trial results showed greater improvements in exercise capacity, symptoms and cardiac biomarkers versus metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy.
- MYQORZO is now the only cardiac myosin inhibitor with a U.S. label comparing its effectiveness with a beta blocker.
- Overall adverse event rates were similar between treatment groups; hypertension occurred more frequently with MYQORZO.
- The drug retains a boxed warning for heart failure risk, requiring echocardiogram monitoring and access through a restricted distribution program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160400PRIMZONEFULLFEED9878065) on November 16, 2026, and is solely responsible for the information contained therein.